Melissa Bradford-Klug

Melissa Bradford-Klug is Chief Business Officer of Citrine Medicine. Citrine Medicine, a therapeutics company focused on rare diseases, raised $80 million in series A funding round led by Quan Capital and other participants were founding investors Eight Roads, F-Prime Capital, Vivo Capital, as well as 3H Health Investment and WU Capital. Launched in 2019, Citrine aims to deliver rare disease drugs to the Chinese market.

Melissa served as Chief Business Officer of Keryx, 2017-2019, where she completed a merger of equals with Akebia. She previously served as Senior Vice President, Strategy and Business Development at AMAG Pharmaceuticals from 2014 to 2016, where she was responsible for shaping the company’s strategy by diversification of the company’s portfolio through business development and acquisitions to become a leading women’s health company. She executed over $1B in M&A to reshape AMAG’s portfolio and was key member of the financing team to secure funding the transactions through equity and debt.

From 2004-2014, Melissa was the Vice President of Corporate Development & Strategy at Mallinckrodt Pharmaceuticals (formerly Covidien). She played a key role in the spin-out of Mallinckrodt from Covidien. She served as the led for Mallinckrodt’s separation planning regarding financial, tax and legal aspects of the separation. She was a key member of strategy team that created Mallinckrodt’s equity value story for the investor community. She executed over $1B of licensing, acquisition and divestments that revitalized Mallinckrodt and Covidien’s portfolios.

Melissa has experience across a variety of functions including marketing, program management and R&D in various roles at Baxter, Eli Lilly, Monsanto, and G.D. Searle (now Pfizer).

Melissa completed her Bachelor of Science degree in Chemistry and earned her Master of Business Administration with an emphasis on Finance from DePaul University. She has completed executive education courses at Kellogg and Harvard Business School and Harvard Public Health. Melissa serves on the board of directors of MassBio. A founding member of Chief Business Officer Forum in Cambridge.